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Background: Crohn’s disease (CD), a chronic inflammatory bowel disease (IBD), occurs in 
genetically susceptible individuals who develop aberrant immune responses to endoluminal 
bacteria. Recurrent inflammation increases the risk of several complications. Despite use of a 
traditional “step-up” therapy with corticosteroids and immunomodulators, most CD patients 
eventually require surgery at some time in their disease course. Newer biologic agents have been 
remarkably effective in controlling severe disease. Thus, “top-down,” early aggressive therapy 
has been proposed to yield better outcomes, especially in complicated disease. However, safety 
and cost issues mandate the need for careful patient selection. Identification of high-risk candi-
dates who may benefit from aggressive therapy is becoming increasingly relevant. Serologic and 
genetic markers of CD have great potential in this regard. The aim of this review is to highlight 
the clinical relevance of these markers for diagnostics and prognostication.
Methods: A current PubMed literature search identified articles regarding the role of biomark-
ers in IBD diagnosis, severity prediction, and stratification. Studies were also reviewed on the 
presence of IBD markers in non-IBD diseases.
Results: Several IBD seromarkers and genetic markers appear to be associated with complex 
CD phenotypes. Qualitative and quantitative serum immune reactivity to microbial antigens 
may be predictive of disease progression and complications.
Conclusion: The cumulative evidence provided by serologic and genetic testing has the potential 
to enhance clinical decision-making when formulating individualized IBD therapeutic plans.
Keywords: Crohn’s disease, serologic testing, inflammatory bowel disease, complicated 
disease, biomarkers
Introduction
Crohn’s disease (CD) is a prevalent chronic inflammatory bowel disease (IBD) marked 
by heterogeneous symptoms indicative of an underlying inflammatory process. The 
hallmark pathology of CD is chronic transmural inflammation, but the phenotypic 
spectrum varies greatly both in location and behavior (ie, stricturing or penetrating 
phenotypes).1 As the disease progresses, persisting inflammation may lead to pen-
etration and strictures, perhaps culminating in medically refractory disease requiring 
multiple hospitalizations and surgical intervention.2–4 The traditional treatment para-
digm includes a “step-up” approach of corticosteroids and immunomodulators, with or 
without biologic agents as severity progresses or patients fail to respond.5–7 Whereas 
this approach may be effective in the near term,8–10 it may not prevent overall disease 
progression.11–13 Within 10 years of diagnosis, more than half of CD patients still require 
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a stricturing or penetrating intestinal complication,2,15 and 
the cumulative risk of hospitalization rises to nearly 80%.16 
Risk of hospitalization is greatest within the first year after 
diagnosis of CD (32%–83% of patients), with the annual 
incidence of hospitalizations remaining steady at 20% over 
the next 5 years.16,17
“Top-down” therapy,7,18 with the earlier introduction 
of biologic agents such as antitumor necrosis factor alpha 
  (anti-TNF-α) antibodies, has demonstrated high rates of 
remission and mucosal healing.19–23 However, the top-down 
approach is not appropriate for all patients, as not all of them 
will develop complicated disease.2,12,16 Early use of immuno-
suppressants or biologics soon after diagnosis may increase 
the risks, including malignancies and infections.7,18 The high 
costs of these therapies24,25 also prohibit top-down therapy as a 
universal approach.7 Therefore, the ability to identify patients 
at risk for developing a complicated disease course is critical 
to the effective use of targeted top-down strategies.
Clinical and nonserologic predictors  
of disease course
Clinical features have some predictive value for prognosis in 
CD, but their interpretation remains problematic. Studies have 
shown that an initial requirement for steroids, young age at 
diagnosis, presence of small bowel, and/or perianal disease 
at diagnosis, and cigarette smoking26–28 are associated with an 
adverse prognosis. However, factors such as referral bias,29 
varying definitions of adverse outcomes, and varying prior 
disease treatments in these studies complicate the prognosis 
and make predictions difficult for the individual CD patient. 
Clinical phenotyping issues remain complex; ongoing efforts 
are being made to standardize a clinical classification scheme 
for IBD.30 Disease localization may be comparable only at 
the time of diagnosis, since CD behavior evolves over time. 
Vernier-Massouille et al31 showed a convergence in rates of 
CD subtypes, with inflammatory (decreasing prevalence) and 
stricturing (increasing prevalence) disease over 10 years of 
follow-up after diagnosis (Figure 1). Most studies suggest that 
ileal disease is an independent predictor of adverse outcomes, 
particularly the need for early surgery.29,32–34 While some 
clinical features do show associations with adverse prognosis, 
they are usually described retrospectively, and many features 
lack standardization. The resulting heterogeneity leads to 
significant difficulty in using these clinical data for creating 
therapeutic algorithms in CD.35
Inflammatory biomarkers such as C-reactive protein 
(CRP), fecal calprotectin, and fecal lactoferrin may be use-
ful in differentiating active IBD from inactive IBD and other 
gastrointestinal disorders,36 as well as measuring response to 
various treatments.37 Pretreatment CRP levels have shown 
utility in predicting treatment response to anti-TNF-α agents 
in CD in some but not all studies.20,38 The value of CRP as 
a pretreatment predictor of severe disease remains mostly 
unknown. Henriksen et al39 found a CRP . 53 mg/L at 
diagnosis to be predictive of a high risk of surgery (82%) 
after 5 years in patients with ileal disease (odds ratio [OR] 
6.0; 95% confidence interval [CI] 1.1–31.9), L1 according to 
the Vienna classification. Although the predictive value of an 
elevated CRP is suggested in this subset (∼30% of those with 
L1 classification),39 the sensitivity and specificity of CRP in 
CD are modest overall. Fecal calprotectin is a natural anti-
biotic, cytoplasmic protein released into the colonic lumen 
by activated polymorphonuclear neutrophil cells and/or 
monocyte-macrophages during cell death. Fecal calprotectin 
levels are elevated in active IBD. Lactoferrin, similar to cal-
protectin, is a glycoprotein component of polymorphonuclear 
neutrophil granules whose concentrations become elevated 
in feces during an acute mucosal inflammatory response. 
Four fecal markers of inflammation – calprotectin (PhiCal™ 
enzyme-linked immunosorbent assay [ELISA] test), 
lactoferrin (IBD-SCAN™ ELISA test), the Hexagon OBTI 
(immunochromatographic test for detection of human hemo-
globin), and LEUKO-TEST (lactoferrin latex-  agglutination 
test) – were evaluated to discriminate irritable bowel syn-
drome (IBS) from IBD in a prospective study.40 Accuracy 
was similar with both fecal lactoferrin and fecal calprotectin 
assays (∼90%), but these tests do not   differentiate between 
various types of inflammatory colitides (ie,  diverticulitis, 
infectious or ischemic colitis). These findings have been 
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Figure 1 Crohn’s disease phenotypic behavior over time, according to Montreal 
classification at diagnosis and follow-up in 404 pediatric patients. Dramatic changes 
occurred in the proportion of disease behavior subgroups – from inflammatory 
nonpenetrating,  nonstricturing  disease  (B1)  to  stricturing  (B2)  or  penetrating 
disease (B3) (P , 0.01). 
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replicated.36 Fecal calprotectin and lactoferrin outperform 
serum CRP or the clinical Crohn’s disease activity index 
at correlating with endoscopic levels of inflammation 
(Spearman’s r = 0.729 and 0.773, respectively; P , 0.001), 
especially colonic inflammation.41 In clinical practice, these 
tests can be used to differentiate between IBD and IBS or to 
corroborate clinical flare-ups.
CD-specific serologic  
and genetic markers
Serologic markers in iBD: role  
of familial studies
Subsets of IBD patients may have abnormal immune 
responses to various microbial antigens.42,43 Antibodies to 
Saccharomyces cerevisiae (ASCA) occur in 50%–70% of 
CD patients.44 The pathophysiological associations of sero-
markers with IBD subtypes are supported by familial studies. 
Atypical antineutrophilic cytoplasmic antibodies (ANCA) are 
associated with ulcerative colitis (UC) in approximately 70% 
of patients,44 although familial studies do not suggest that 
ANCA has genetic underpinnings. Papo et al45 and Folwaczny 
et al46 both found no increase in ANCA prevalence among 
unaffected relatives of IBD patients (∼3%–5%). Perinuclear 
ANCA (pANCA) was subsequently associated with Crohn’s 
colitis.47 
In contrast, ASCA has shown strong familial associations, 
suggesting its primary role as a stable biomarker in CD. 
Sendid et al48 found 20% of unaffected relatives were ASCA-
positive in CD families versus less than 1% of unaffected 
relatives in control families. A Belgian study also found 
similar results (21%)49 but showed that ASCA is not associ-
ated with any alteration in intestinal permeability. An Italian 
study demonstrated elevated ASCA (∼25%) in unaffected 
relatives of IBD patients, which included purely UC-affected 
families.50 These investigators concluded there may be a pri-
mary genetic influence on ASCA status in IBD families. The 
possible genetic underpinnings of ASCA in CD are complex. 
An IBD twin study found only a 5% seroprevalence of ASCA 
among 20 unaffected (discordant) monozygotic twins with a 
CD sibling, versus 26% among 27 discordant dizygotic twins. 
This suggests the importance of shared environmental factors 
in familial CD.51 However, there still may be a genetic com-
ponent to ASCA. Seibold et al52 showed that ASCA positivity 
is associated with mutations in the mannan-binding lectin 
(MBL) gene that result in MBL deficiency. The physiologic 
role of MBL includes immune   recognition of yeasts and 
other mannose-expressing pathogens.53 Hence, it may be that 
ASCA seroreactivity occurs when such pathogens are able 
to penetrate a permeable intestinal barrier, especially in the 
setting of MBL   deficiency.53 Newer IBD markers (described 
below) have also shown increased familial expression,54 par-
ticularly for CD. 
A natural question that follows from familial ASCA is 
whether ASCA presence positively predisposes to future CD 
development. The literature on this issue is sparse. One study 
of 102 ASCA-positive first-degree relatives of IBD patients 
revealed a less than 2% cumulative incidence of IBD over 
7 years.55 In a nonfamilial study, Israeli et al56 found 31% ASCA 
seropositivity before CD diagnosis in military recruits. An addi-
tional 23% of CD patients seroconverted after CD diagnosis, 
and none of the 95 non-IBD controls were   ASCA-positive 
over the same 38-month median follow-up. Prospective studies 
would be most informative in this regard.
iBD diagnostics: serologic markers  
as a screening or diagnostic tool
If seromarkers such as ASCA do precede CD development 
in as many as one-third of individuals, the positive predictive 
value (PPV) of the test becomes a relevant issue. Several 
recent studies have shed light on the spectrum of non-IBD 
diseases demonstrating ASCA phenomena (Table 1).57–65 
Data for newer IBD markers are not yet available, and 
clinicians using serologic markers in the evaluation of IBD 
should be aware of this. ASCA was originally reported as an 
antibody to the nonpathogenic yeast  S. cerevisiae in CD.43,66 
However, the clinically relevant yeast Candida albicans 
also expresses ASCA epitopes under conditions favoring 
their virulence; a study from the ASCA-pioneering group 
in Lille, France,57 confirmed that 100% of patients with 
systemic candidiasis have acute ASCA titers above cutoff 
values considered significant in CD. However, this does 
not preclude the role of ASCA in CD. Candida albicans 
may be of greater relevance to CD than S.cerevisiae, which 
has never been considered pathogenic in CD. The same 
group57 confirmed that C. albicans is an immunogen for 
ASCA in CD and is more prevalent in healthy relatives of 
patients with CD.67 Bacterial infections and other chronic 
diseases may also generate ASCA positivity in some indi-
viduals (Table 1).58 Rates of 21%–44% seropositivity have 
been reported in cystic fibrosis. Bacterial infection was 
suspected of playing a role in this context.59,60 Intestinal 
tuberculosis, highly prevalent in many areas of the world, 
may be difficult to clinically or endoscopically distinguish 
from CD.68 Makharia et al61 reported   seropositivity rates 
of 43% for immunoglobulin A (IgA) and 47% for ASCA Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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in Indian patients with   intestinal tuberculosis, rates that did 
not differ from those in CD patients.   Noninfectious diseases 
considered in a differential diagnosis of IBD may also 
demonstrate ASCA phenomena. For example, ASCA titers 
may be elevated in untreated celiac disease and disappear 
completely after introducing a gluten-free diet. This suggests 
that abnormal intestinal permeability plays an important role 
in ASCA generation, as well as for other antibodies in celiac 
disease.62 ASCA positivity may also reflect a phenotypic 
continuum between ulcerative jejunitis, celiac disease, and 
classical CD. Occasionally, clinicians will encounter patients 
with IBD or suspected IBD, or with associated diseases such 
as ankylosing spondylitis or rheumatoid arthritis. In these 
settings, ASCA has been shown to be nonpredictive of 
occult IBD.69 In addition, pANCA has been associated with 
autoimmune hepatitis (AIH) type 1, particularly in men and 
in those AIH-1 patients with smooth muscle antibody of 
the anti-actin type.70 Therefore, caution is required when 
interpreting positive tests in such patients, particularly those 
without gastrointestinal symptoms. Testing for ASCA alone 
may have limited usefulness in predicting CD. Furthermore, 
there is clinical overlap of ASCA in UC.
These limitations have led to the development of serologic 
marker combinations in panels to increase their predictive 
values (Table 2).71–76 Sandborn and colleagues77 reported a 
PPV of 86% for CD with the ASCA-positive/ANCA-negative 
combination. Similarly, Peeters et al78 reported a PPV of 
91% for this combination. The predictive value is increased 
by testing ASCA for both IgA and IgG (immunoglobulin 
G) subfractions.79 However, a meta-analysis of more than 
60 ASCA and ANCA studies in IBD80 showed a modest 
overall sensitivity of the ASCA-positive/ANCA-negative 
combination for CD (55%) (Table 2).44,78,80–86 Several novel 
bacterial antigens in CD have been identified as potentially 
useful in serologic testing. Approximately 55% of CD 
patients test positive for antibodies to Escherichia coli outer 
membrane porin C (anti-OmpC)87 and for antibodies to a 
bacterial sequence derived from Pseudomonas fluorescens 
(anti-I2). Reactivity to CBir1 flagellin, a colitogenic antigen 
of the enteric flora in C3H/HeJBir mice strain, is highly 
prevalent (50%) in CD.88 In addition, anti-CBir1 is detected 
in patients who are nonreactive to the ASCA, OmpC, I2, 
and ANCA antigens.89 Recently, a class of antibodies called 
antiglycans have been shown to be prevalent in CD.90 These 
homogeneous antibodies are directed against carbohydrate 
moieties on cell surfaces of erythrocytes, immune cells, and 
microorganisms.90
Investigators have sought to define specific patterns of 
reactivity with serologic biomarkers. Such patterns may better 
distinguish CD from UC or further characterize patients with 
indeterminate colitis, possibly into a CD or UC diagnosis. 
Computer algorithm modeling of clinical pattern recognition 
has been developed to facilitate pattern recognition.80,87,91 For 
example, the presence of anti-CBir1 and pANCA antibodies 
among CD patients can help to distinguish between UC and 
a UC-like CD phenotype.89 In addition, when combined with 
ASCA and pANCA   testing, anti-OmpC and anti-I2 antibod-
ies can help identify up to 84% of patients with CD; this 
yield drops to 54% when ASCA is considered alone.87
iBD prognostics: individual serologic 
markers and CD disease behavior
While initially used for diagnostic purposes, serologic pan-
els are more useful in clinical practice for their prognostic 
information. While each serologic marker is associated with 
some form(s) of complicated disease behavior, a   qualitative 
Table 1 Seroprevalence of ASCA positivity, igA and igG in non-iBD disease
Disease ELISA assay ASCA 
IgA
ASCA 
IgG
ASCA 
IgA or IgG
Study
Systemic candidiasis Lille assay, inhouse – – 100% Standaert-vitse et al57
various acute bacterial infections Aesku Diagnostics, Germany – – 22% Berlin et al58
Cystic fibrosis, pediatric Quanta-Lite, inova Diagnostics, USA 13% 11% 21% Condino et al59
Cystic fibrosis, adult Quanta-Lite, inova Diagnostics, USA 44% – – Lachenal et al60
intestinal tuberculosis Aesku Diagnostics, Germany 43% 47% 67% Makharia et al61
Celiac disease (pre-treatment) Quanta-Lite, inova Diagnostics, USA 20% 54% 59% Granito et al62
Type 1 diabetes mellitus Orgentec, Germany 10% 21% 25% Sakly et al63
Primary biliary cirrhosis Quanta-Lite, inova Diagnostics, USA 19% 11% 23% Muratori et al64
Primary sclerosing cholangitis Quanta-Lite, inova Diagnostics, USA 32% 28% 44% Muratori et al64
Autoimmune hepatitis Quanta-Lite, inova Diagnostics, USA 12% 16% 18% Muratori et al64
Ankylosing spondylitis Quanta-Lite, inova Diagnostics, USA 23% 12% – Riente et al65
Rheumatoid arthritis Quanta-Lite, inova Diagnostics, USA 18% 10% – Riente et al65
Abbreviations: ASCA, antibodies to Saccharomyces cerevisiae; ELISA, enzyme-linked immunosorbent assay; IBD, inflammatory bowel disease; IgA, immunoglobulin A; IgG, 
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Table 2 Summary of seromarker characteristics in iBD
Seromarker Antigenic determinant Disease indication Sensitivity, specificity, 
PPV, NPV
ASCA Mannose residue forms the 
phosphopeptidomannan of the cell 
wall of Saccharomyces cerevisiae; 
also expressed by Candida albicans
CD
•   Sensitivity for CD improved when 
used in combination with pANCA
Sensitivity: 53%80
Specificity: 89%80
PPv: 73%a,81
PPv: 84% with (-) pANCA81
NPv: 68%78
pANCA Unidentified protein of the nuclear 
envelope of neutrophils
UC
•   May be (+) in CD with UC-like phenotype
•   May predict chronic pouchitis 
following iPAA
Sensitivity: 55%80
Specificity: 89%80
PPv: 82%a,81
NPv: 89%78
Anti-OmpC Outer membrane porin, originally 
isolated from Escherichia coli87
CD
•   May identify CD in up to 15% 
of ASCA (-) patients
Sensitivity: 20%–55%44
Specificity: 89%44
PPv: 83.4%b,82
NPv: 25.3b,82
Anti-i2 Bacterial sequence derived 
from Pseudomonas fluorescens
CD Sensitivity: 42%44
Specificity: 76%44
PPv: 96%c,83
NPv: 26%‡c,83
Anti-CBir1 Flagellin, CBir (Clostridium subphylum) CD
•   May help to differentiate CD 
from UC in pANCA (+) patients
Sensitivity: 50%c,84
Specificity: 53%c,84
PPv: 45%c,85
NPv: not reported
Combination seromarker 
panel (Prometheus iBD 
Serology – 7)
ASCA (igA, igG), anti-OmpC, anti-CBir1, 
NSNA with iFA perinuclear pattern and 
DNAse sensitivity
Differentiating iBD from non-iBD, 
and CD from UC
Sensitivity: 80%86
Specificity: 61.5%86
PPv: 68%86
NPv: 75%86
Notes: avalue reported for distinguishing CD from UC; bUsing expanded-spectrum igA antibody to multiple outer membrane porins (Omp); cExclusive pediatric cohort.
Abbreviations:  ASCA,  antibodies  to  Saccharomyces  cerevisiae;  CD,  Crohn’s  disease;  IBD,  inflammatory  bowel  disease;  IFA,  indirect  fluorescent-antibody  assay; 
IgA, immunoglobulin A; IPAA, ileal pouch-anal anastomosis; NPV, negative predictive value; NSNA, neutrophil-specific nuclear auto-antibodies; OmpC, outer membrane 
porin C; pANCA, perinuclear ANCA; PPv, positive predictive value; UC, ulcerative colitis.
response to multiple markers is more predictive of a 
severe course in CD. Studies in CD have correlated ASCA 
reactivity with increased risk of surgery within 3 years of 
diagnosis,92 small bowel disease location,93 early age at 
diagnosis, and a complicated disease course.94 Additional 
CD studies have linked pANCA levels to UC-like dis-
ease behavior47,94 and a lack of fibrostenosing/penetrating 
disease.93,94 In UC patients undergoing ileal pouch anal 
anastomosis, high levels of pANCA before proctocolectomy 
are associated with development of chronic pouchitis.95,96 
The next generation of serologic markers after ASCA and 
pANCA have been associated with an aggressive disease 
course in CD (Table 3). Anti-OmpC and anti-I2 are associ-
ated with fibrostenosing and internal-perforating disease 
behavior as well as small bowel surgery.50,71,73   Additionally, 
multivariate logistic regression analysis has shown that 
these two markers are independently associated with a 
complicated CD phenotype and/or surgery.71 Patients who 
express anti-CBir1 are nearly twice as likely to develop 
small bowel disease and complicated phenotypes such as 
fibrostenosis and internal-perforating disease.89 A recent 
study reported that anti-CBir1 can be predictive of the 
development of pouchitis after ileal pouch anal anastomosis 
in   pANCA-positive patients.96
Serologic panels and disease 
behavior
An association between severe, complicated CD and high-
level immune responses was confirmed in multiple studies 
analyzing quantitative antibody levels in panels of serologic 
markers (Table 3). In 2004, Mow et al71 associated cumula-
tive antibody responses to I2 and OmpC with distinct disease 
phenotypes. Sera from 303 CD patients were analyzed for 
anti-I2, anti-OmpC, and ASCA. Quartile scores of 1–4 were 
assigned to the individual antigens based on antibody levels 
measured; a quartile sum score (range 3–12) was derived for 
each patient to represent the cumulative quantitative immune 
response to all four antigens.71 Patients with a qualitative anti-
gen reactivity to I2, OmpC, and oligomannan (ASCA) were 
more likely to develop complicated disease (fibrostenosing 
and internal-perforating disease) and require small bowel 
surgery than patients expressing fewer than three antibod-
ies (P # 0.001).71 Quartile sum score analysis suggested 
that the magnitude of antibody responses to I2, OmpC, Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Table 3 Studies of serologic panels in predicting disease phenotype in Crohn’s disease
Study Year Design Population N Serologic 
markersa
Key findings
Mow et al71 2004 Retrospective Adult 303 ASCA, anti-OmpC, 
anti-i2
•   Anti-i2, anti-OmpC, and ASCA were each individually 
associated with iP/S disease or small bowel surgery
•   Patients seropositive for anti-i2, anti-OmpC, and ASCA 
were more likely to develop complicated disease 
behavior than those with reactivity to 2, 1, or 0 
markers (P # 0.001)
•   Percentage of patients with complicated disease increased 
with increasing magnitude of antibody response
Arnott et al72 2004 Retrospective Adult 142 ASCA, anti-OmpC, 
anti-i2
•   Presence and magnitude of responses associated with 
small bowel disease (P = 0.02), disease progression 
(P , 0.001), perforating disease (P = 0.008), and 
surgery (P , 0.001)
Papadakis et al73 2007 Retrospective Adult 731 ASCA, anti-OmpC, 
anti-i2, anti-CBir1
•   Confirmed that anti-CBir1 is independently associated 
with complicated CD phenotype (P = 0.0004)
•   Proportion of patients with iP/S disease increased with 
increasing reactivity to all 4 antigens
•   Addition of anti-CBir1 reactivity enhanced 
discrimination of CD phenotypes, particularly 
complicated disease (iP/S), small bowel involvement, 
and UC-like disease
Dubinsky et al74 2006 Prospective Pediatric 196 ASCA, anti-OmpC, 
anti-i2, anti-CBir1
•   Anti-OmpC (P = 0.0006) and anti-i2 (P = 0.0034) were 
associated with iP/S disease
•   Frequency of iP/S disease increased with increasing 
number of immune responses (P = 0.002)
•   OR of developing iP/S disease was highest among 
children with all 4 immune markers (OR 11.0; 95%  
Ci 1.5–80.4; P = 0.03)
Dubinsky et al75 2008 Prospective, 
longitudinal
Pediatric 796 ASCA, anti-OmpC, 
anti-CBir1
•   Frequency of iP/S disease and surgery increased 
significantly with both the number of immune responses 
(P , 0.0001) and magnitude of responses (P , 0.0001)
•   immune reactivity to OmpC and CBir1 and presence 
of ASCA were associated with faster progression to 
complicated disease and surgery, significantly faster 
than reactivity to 1 or 2 antigens (P , 0.0001)
•   The magnitude of immune response also influences faster 
progression to complicated disease and surgery (P , 0.0001)
ippoliti et alb,76 2009 Retrospective Adolescent 
and adult
731 ASCA, CBir1,  
OmpC, 
i2, NOD2
•   NOD2 was associated with small bowel disease 
involvement (P , 0.001), fibrostenosing phenotype 
(P , 0.0001), history of small bowel surgery (P , 0.05), 
and inversely with UC-like phenotype (P , 0.01)
•   The prevalence of fibrostenosis was significantly associated 
with the number of positive antibodies as well as QSS
•   with combined serologic reactivity and NOD2 status, 
ORs for developing fibrostenotic disease were greater 
with presence of NOD2 variants and also increased 
with higher QSS
Notes: apANCA was measured in some studies but not calculated with the antibodies to determine cumulative association with aggressive disease; bippoliti et al studied CD 
patients’ seroreactivity and their NOD2 status.
Abbreviations: ASCA, antibodies to Saccharomyces cerevisiae; CD, Crohn’s disease; CI, confidence interval; IP/S, internal-penetrating/stricturing disease; NOD2, nucleotide 
oligomerization domain 2; OmpC, outer membrane porin C; OR, odds ratio; QSS, quartile sum score; UC, ulcerative colitis.
and   oligomannan was also associated with complicated small 
bowel disease (Figure 2).71 In a similar study, Arnott et al also 
found that the presence and magnitude of anti-OmpC, anti-I2, 
and ASCA were significantly associated with complicated 
disease (Table 3).72 Papadakis et al73 examined a serologic 
panel that included anti-CBir1 in addition to ASCA, anti-I2, 
and anti-OmpC to predict disease severity in 731 patients 
with CD. Quartile sum scores for this cohort revealed that 
increasing levels of reactivity to all four antigens were associ-
ated with fibrostenosing and internal-perforating disease.73 Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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When added to the quantitative responses to the other three 
antigens, anti-CBir1 reactivity enhanced the discrimina-
tion of complicated disease phenotypes (fibrostenosing or 
internal penetrating), small bowel involvement, and UC-like 
behavior.73 Dubinsky et al74,75 conducted the first two pro-
spective studies in pediatric CD patients that demonstrated 
a relationship between serologic responses and aggressive 
disease behavior. In the first study in 196 patients tested for 
anti-I2, anti-OmpC, ASCA, and anti-CBir1, the frequency 
of complicated disease behavior increased as the number of 
immune responses increased; the presence of four positive 
markers was associated with the highest likelihood of aggres-
sive disease (Table 3).74 These initial findings were confirmed 
in another, larger study of 796 pediatric CD patients using 
ASCA, anti-OmpC, and anti-CBir1.75 The frequency of 
internal-penetrating disease, stricturing disease, and surgery 
increased substantially with both the number and magnitude 
of immune responses.75 Kaplan–Meier estimates for time to 
development of internal-penetrating/stricturing disease and 
CD-related surgery by quartile sum scores are presented 
in Figure 3.75 In both instances, time to adverse outcome 
  (complex disease, surgery) is generally shorter in those 
patients with the highest quartile scores, whereas those in 
the lowest quartile have a very high probability of remaining 
free of adverse outcomes over long periods. The prospective 
design of these studies supports the use of serologic testing 
to predict future disease behavior.74,75
Future directions
Genetic markers in assessing  
aggressive disease behavior
The identification of genetic markers in CD is an active area 
of research.7,71,97–101 The nucleotide oligomerization domain 
2 (NOD2), also known as caspase-activating recruitment 
domain 15 (CARD15) at the IBD1 locus is the first major 
susceptibility gene described for CD.102–104 Three major-effect 
NOD2/CARD15 variants have been found to account for the 
majority (81%) of over 30 such allelic mutations in CD; the 
mutations R702W, G908R, and 1007fs being designated 
as single nucleotide polymorphisms (SNPs) 8, 12, and 13, 
respectively.100,102 Data from across the general population sug-
gest a low penetrance for NOD2/CARD15 mutations. However, 
among CD patients, each of the three SNPs has been shown 
to be independently associated with development of symp-
toms, with the greatest risk conferred by the SNP13 mutant 
allele and in those with multiple mutations.104–106 The NOD2/
CARD15 variant genotypes have been associated with severe 
CD phenotypes.97,98,100,101,107,108 Abreu et al97 compared NOD2/
CARD15   genotypes to serum immune markers, disease 
behavior, and disease location in two consecutive cohorts of 
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CD patients (Table 4).   Multivariate analysis showed a sig-
nificant association between the NOD2/CARD15 variants and 
fibrostenosing disease (OR 2.8; 95% CI 1.3–6.0; P = 0.011).97 
In addition, the risk of developing fibrostenosing disease was 
greatest among carriers of two mutations (OR 7.4; 95% CI 
1.9–28.9; P = 0.004). Similar findings have been observed in 
large European100,107 and American71,98 cohorts.
Genome-wide association studies have identified 
approximately 71 CD-associated gene susceptibility loci, 
with potentially many more genes.104 Some of these have 
been assessed for their relationship to CD phenotype and 
disease course. Weersma et al109 examined genetic variants, 
including NOD2/CARD15, Drosophilia discs homolog 5 
(DRG5), autophagy-related 16-like 1 gene (ATG16L1), and 
the interleukin 23 receptor gene (IL23R). Results showed that 
an increase in the number of allelic variants or genotypes was 
associated with an increased risk of developing CD and hav-
ing a complicated disease course.109 These findings suggest 
that it is possible to assess a given patient’s genetic profile to 
determine risk of complicated disease.
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Synergism between serologic phenotypes 
and genetic variants
Emerging data from studies of familial expression of ASCA, 
anti-OmpC, and other IBD serologic markers suggest that 
genetic mutations lead to alterations in the expression of anti-
bodies to microbial antigens.49,54,99,101,110–112 Anti-CBir1 and 
ASCA expression were linked to NFKB1 haplotypes and sub-
sequently to reductions in NF-kB activation, thus describing 
another link between innate and adaptive immunity in IBD.113 
Studies have not always concurred regarding the association 
between NOD2/CARD15 polymorphisms and seromarkers 
in IBD.99,110,114 However, NOD2/CARD15 variants seem to 
be more common in patients testing positive for multiple 
serologic markers, including those with high antibody levels 
(elevated quartile sum scores) (Figure 4).101,111 Ippoliti et al76 
determined that a combination of altered innate and adap-
tive immune responses act synergistically to increase the 
development of complicated CD, particularly fibrostenosing 
disease. After grouping patients by serologic quartile sum 
scores of 4–6, 7–9, 10–13, and 14–16 and subdividing by 
the presence or absence of NOD2/CARD15, they calculated 
ORs for developing fibrostenotic disease (Table 5). The ORs 
were significantly greater among patients with the presence 
of NOD2 variants than those without. The ORs were also 
increased with higher quartile sum scores.
Future diagnostic tests may quantitatively assign a risk 
probability for severe disease by using algorithms that 
analyze these serologic and genetic biomarkers. A new CD 
prognostic test was recently made available. This serogenetic 
panel is composed of seven assays for nine markers, includ-
ing six serologic biomarkers, specifically ASCA-IgA, 
ASCA-IgG, anti-OmpC, anti-I2, anti-CBir1, and pANCA. 
In addition, the test recognizes three NOD2 gene variants 
(SNP8, SNP12, and SNP13). The prognostic panel calculates 
Table 4 Significant individual associations of antibody responses and NOD2/CARD15 genotype with Crohn’s disease phenotypes71,89,97
Marker Significant individual associations
Small bowel 
involvement
Complicated 
CD phenotypea
Small bowel 
surgery
UC-like 
behavior
ASCA Yes Yes Yes Yes (negative)
pANCA Yes (negative) Yes (negative) Yes (negative) Yes
Anti-i2 No Yes Yes No
Anti-OmpC No Yes Yes No
Anti-CBir1 Yes Yes No No
NOD2b Yes Yes No Yes (negative)
Notes: aComplicated CD phenotypes include fibrostenosing or internal-perforating disease; bNOD2 is a CD susceptibility gene.
Abbreviations: ASCA, antibodies to Saccharomyces cerevisiae; CARD15, Caspase-activating recruitment domain 15; CD, Crohn’s disease; NOD2, nucleotide oligomerization 
domain 2; OmpC, outer membrane porin C; pANCA, perinuclear ANCA; UC, ulcerative colitis.
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probability of complications curve based on antibody quartile 
sum scores and NOD2/CARD15 mutation status. The results 
are then analyzed by a logistic regression algorithm to quan-
tify the likelihood that a patient will progress to a complicated 
CD phenotype. The test output is a probability score reflecting 
the likelihood of disease progression to complications.115
Current research in identifying predictors 
of treatment response
Another area of growing interest that has potential to con-
tribute to a personalized approach in CD is the prediction 
of response to medical therapies, particularly biologic 
agents.116,117 Some clinical features have been shown to 
influence response to infliximab. In a prospective study in 
74 CD patients, Arnott et al116 found that smoking signifi-
cantly influences response to infliximab, with smokers less 
likely to respond at 4 weeks (OR 0.24; 95% CI 0.06–0.91; 
P = 0.035) and more likely to relapse at 1 year (relative 
risk 3.2; P = 0.0026) than nonsmokers. Other factors that 
had predictive value were colonic disease, which increased 
the likelihood of response at 4 weeks nearly five-fold, and 
concomitant immunosuppression, which was associated with 
reduced risk of relapse at 1 year.116 In addition, detectable 
trough serum concentrations of infliximab (irrespective of 
antibody formation) have been shown to be associated with 
higher rates of clinical and endoscopic remission.117 Investi-
gators have begun to explore the relationship of various sero-
logic markers with response to medical therapies. Sandborn 
et al118 found an increased frequency of pANCA positivity 
in patients with left-sided UC that was resistant to oral and 
rectal 5-aminosalicylates and corticosteroids. In 2004, Mow 
et al119 reported the results of a small pilot study that sug-
gested serum reactivity to microbial antigens, particularly to 
OmpC and I2, would help to predict response to combination 
antibiotic therapy. Finally, the utility of serologic markers 
in predicting response to biologic agents was explored, 
with one study demonstrating an insignificant trend toward 
lower response rates to infliximab with the pANCA-positive/
ASCA-negative combination in CD120 and another associat-
ing the same combination with suboptimal early clinical 
response to infliximab in UC (OR 0.40; 95% CI 0.16–1.00; 
P = 0.049).121 Investigators developed an algorithm to predict 
response to infliximab using a previous cohort of 287 patients 
with inflammatory or fistulizing CD and combining key 
clinical predictors (ie, age ,40 years, concurrent use of 
immunosuppressants, disease location, and CRP levels) 
and pharmacogenetic data of three apoptotic SNPs (Fas 
ligand-843 C/T, Fas-670 G/A, and Caspase9 93 C/T).122 
The algorithm for inflammatory disease enabled prediction 
of response rates of 21.4%–100% and remission rates of 
15.8%–85.7%, while the algorithm for fistulizing disease 
enabled prediction of response rates of 46.6%–100% and 
remission rates of 20%–57.6%.122 Recently, Dubinsky et al123 
indicated that a combination of a phenotype, serotype, and 
genotype is the best predictive model of nonresponse to 
anti-TNF-α agents in pediatric patients. Specifically, the 
most predictive model included the presence of three novel 
“pharmacogenetic” loci, the IBD-associated loci BRWD1, 
pANCA, and a UC diagnosis (P , 0.05 for all). The relative 
risk of nonresponse increased 15 times as the number of risk 
factors increased from 0–2 to $3 (P , 0.0001).123
Impact of predictive factors
Current evidence suggests that a combination of clinical 
findings (eg, smoking) and the measurement of immune 
responses with serologic testing – in combination with 
genetic testing – can help to predict disease behavior.124 
Moreover, evidence shows that these tools may be used 
to stratify patients at the time of diagnosis on the basis of 
their risk of developing aggressive disease.124 Screening 
for NOD2/CARD15 genetic variants early in the patient’s 
disease course may also provide additional evidence to 
suggest a patient’s likelihood of disease progression and 
allow clinicians to tailor therapeutic strategies based on the 
aggressiveness of IBD subtype.124 Early aggressive interven-
tion would then be delivered to high-risk patients and less 
intensive therapies to those more likely to have a benign 
disease course. While serogenetic testing for diagnosing 
disease, predicting disease course, or determining treatment 
options5 is not routinely used, clinical practice guidelines 
may ultimately evolve to include a therapeutic algorithm 
recommending use of top-down therapy in patients with or 
Table 5 Demonstration of synergism between NOD2 variants 
and antibody levels in fibrostenosis
Quartile Presence of 
NOD2 variant?
Odds ratio 
(confidence limits)
P value
4–6 No
Yes
Reference
0.2 (0–1.2)
Reference
7–9 No
Yes
1.2 (0.6–2.2)
2.7 (1.3–5.5)
0.004
10–13 No
Yes
3.3 (1.8–6.0)
7.3 (3.7–14.4)
0.003
14–16 No
Yes
4.8 (2.3–10.1)
9.6 (4.2–21.8)
0.01
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at risk for   complicated disease behavior, as assessed by the 
combination of clinical characteristics and serologic and 
genetic findings.11   Furthermore, the identification of new 
pathogenetic treatments, including cytokines (eg, IL-23, 
IL-17), diapedesis inhibitors (eg, natalizumab, vedolizamab), 
and chemokine receptor antagonists (eg, CCX282-B), offer 
the promise of targeted biologic therapies. Future generations 
of IBD serologic profiles/genetic testing can be anticipated 
to play a role in identifying optimal biologic family thera-
peutic options.
Conclusion
Given the evidence to support the use of a top-down treatment 
approach, it is imperative to identify patients who are most 
likely to benefit from this strategy. Although clinical charac-
teristics alone can help to predict a complicated disease course, 
these features lack the accuracy to effectively influence thera-
peutic decisions. Information gained from serologic testing, 
both qualitatively and quantitatively, can assist in determining 
the likelihood of a complicated CD. This personalized approach 
may be further improved with the incorporation of knowledge 
regarding NOD2/CARD15 and other novel CD-associated 
genetic polymorphisms. Growing evidence suggests that the 
aberrant IBD innate immunity reflects underlying genetic 
determinants in CD patients. The subsequent maladaptive auto-
immune response is in turn reflected by the presence of IBD 
serologic markers. Taken together, the patient’s clinical and 
serogenetic profile may be used to inform clinicians regarding 
a patient’s prognostic risk and help guide treatment decisions 
to alter the future natural history of CD now.
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